PrograMS

Longitudinal prediction of progression in MS: 'The Amsterdam MS Cohort'

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21916

Enrollment

260

Registered

2021-04-07

Start date

2021-05-25

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All people with MS and all healthy controls who have previously participated in the Presto (local ethics committee number: 2002/140), GeneOCT (2004/9), or LTD (2010/336) studies (collectively also known as the “Amsterdam MS Cohort”) and have not provided objection to be contacted for follow-up study, or have been enquired to join the cohort based on the Amsterdam MS Cohort (2020/269) protocol.

Exclusion criteria

Exclusion criteria: MS patients unable to undergo the minimal data collection (as described in Methods section) or comorbidity that interferes with participation in this study (controls).

Design outcomes

Primary

Measure	Time frame
Our primary outcome is longitudinal cognitive decline, as measured by neuropsychological assessment (NPE).	—

Secondary

Measure	Time frame
Our secondary outcome is clinical progression, defined by worsening physical disability (EDSS). Parameters/predictors: Functional brain changes (functional MRI and magnetoencephalography, MEG); structural brain changes (MRI), ophthalmologic measurements (optical coherence tomography – OCT, and eye movements) and blood biomarkers.	—

Contacts

Public ContactZoë van Lierop

VU medical center

z.vanlierop@amsterdamumc.nl0031204441966

Outcome results